RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
about
Dose-dependent Toxicity of Humanized Renilla reniformis GFP (hrGFP) Limits Its Utility as a Reporter Gene in Mouse MuscleProspect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.RNAi-mediated Gene Silencing of Mutant Myotilin Improves Myopathy in LGMD1A Mice.Genome engineering: a new approach to gene therapy for neuromuscular disorders.Precision medicine for cardiovascular disease : Learning lessons from cardiomyopathies.
P2860
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@ast
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@en
type
label
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@ast
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@en
prefLabel
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@ast
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@en
P2860
P1433
P1476
RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.
@en
P2093
Scott Q Harper
P2860
P304
P356
10.2174/156652312802083585
P407
P577
2012-08-01T00:00:00Z